7 results about "Meticillin" patented technology

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The application discloses an application of near-infrared controllable Fe, Zn doped tea polyphenol based carbon dot nanometer enzyme in fruit preservation, and belongs to the technical field of agricultural product preservation.The application takes tea polyphenol as a precursor, and prepares Fe, Zn doped carbon dots (Fe, Zn@GTP) nanometer enzyme with excellent antioxidant and antibacterial activity through a microwave assisted method.The Fe, Zn@GTP nanometer enzyme exhibits near-infrared light enhanced peroxidase, superoxide dismutase and catalase catalytic activity and photo-thermal performance.The Fe, Zn@GTP has antibacterial effects on escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, ampicillin-resistant escherichia coli and penicillium expansum, and the inhibition rate of the bacterial biofilm treated by the Fe, Zn@GTP is more than 90%.In the preservation experiment, the PVA / Fe, Zn@GTP film can effectively prolong the preservation period of fruits, significantly reduce the occurrence rate of fruit mold and browning, and the deterioration degree of quality indexes.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

This invention belongs to the field of antibacterial nanomaterials, specifically relating to nanoparticles that inhibit methicillin-resistant Staphylococcus aureus (MRSA) resistance. The nanoparticles have a three-layer structure, consisting of a core layer composed of a copper nanoparticle and a copper oxide composite, a mesoporous graphite shell, and a bis(amino)PEG coating, from the inside out. The above method achieves physical encapsulation of copper nanoparticles by graphite using a one-step plasma arc method; and constructs a Cu / Cu₂O interface through precise oxygen-controlled thermal oxidation treatment, while simultaneously achieving effective protection and exposure of the active A layer by mesoporousizing the graphite; the use of bis(amino)PEG to form a polymer coating on the nanoparticles enhances bacterial uptake capacity and improves biocompatibility. The nanoparticles prepared by this invention can increase the utilization rate of drug-resistant bacteria by inhibiting bacterial biofilm structures and efflux pumps that cause bacterial infections, thereby improving the clearance capacity against drug-resistant bacterial infections and demonstrating great potential for application and clinical translation.

This invention relates to a novel methicillin-resistant Staphylococcus aureus (MRSA) bacteriophage and its applications. The invention provides a methicillin-resistant MRSA bacteriophage SP01, which is identified as a new species. This phage possesses highly efficient lytic ability against MRSA and has a broad host spectrum, showing sensitivity to multiple clinical isolates. Furthermore, phage SP01 exhibits excellent environmental stability, maintaining good activity within a temperature range of 4–40°C and a pH range of 7–11. In summary, this invention allows for the preparation of drugs, disinfectants, and bactericides for treating MRSA infections using phage SP01, addressing the problem of conventional antibiotic ineffectiveness and demonstrating broad application prospects.

The present application aims to provide a eucheuma extract, a preparation method and application thereof, and the preparation method comprises the following steps: cutting eucheuma whole grass, using distilled water and 75% ethanol as extraction solvents respectively, hot reflux extraction twice, combining the filtrates, concentrating under reduced pressure, and evaporating the solvent to dryness to prepare a dry paste, and obtaining eucheuma water extract and eucheuma alcohol extract respectively. The eucheuma water extract and alcohol extract provided by the present application have significant inhibitory effects on staphylococcus aureus, escherichia coli, staphylococcus epidermidis, methicillin-resistant staphylococcus epidermidis, sarcina, bacillus, pseudomonas aeruginosa, enterococcus faecium, micrococcus luteus, acinetobacter baumannii, streptococcus pneumoniae and klebsiella pneumoniae, and have great development potential in the future research on bacteriostatic drugs, bacteriostatic cleaning products and other bacteriostatic products.